The Senate Finance Committee is hammering out a bipartisan bill while other leaders will drive ultimate implementation
Sen. Max Baucus (D-Mont.) is chairman and appears more of a centrist, seeking a bill some Republicans would support.
Sen. Jeff Bingaman (D-N.M.), also on the Health Committee, wants a public-plan option-Democrats' main focus right now.
Sen. Michael Enzi (R-Wyo.) is also on the Health Committee and voted against the healthcare bill that contained a public plan.
Sen. Charles Grassley (R-Iowa) has taken a lead for Republicans on reforms and is known for keeping watch on spending. He favored private competition for Medicare Part D.
Sen. Olympia Snowe (R-Maine) could offer the pivotal vote. A small-business advocate, she opposes taxing employer-sponsored benefits.
There are influential players along the sidelines, too. Some will sway final votes, and others will have responsibilities in the implementation of policy changes (if any).
Nancy-Ann DeParle, the "health reform czar," has listened to the voices of industry groups.
Sen. Chris Dodd (D-Conn.), member of the Senate Health, Education, Labor and Pensions Committee, is leading negotiations in the absence of the committee's chairman, Sen. Edward Kennedy.
Ezekiel Emanuel, author, professor, oncologist and special advisor for health policy to the director of the White House Office of Management and Budget, helps the President craft his health policy strategy. His brother Rahm is chief of staff.
Sen. Orrin Hatch (R-Utah) co-sponsored the legislation that created the State Children's Health Insurance Program. He represents a potential vote on a bipartisan bill.
Peter Orszag, director, Office of Management and Budget, drives the administration's decisions around cost and is a supporter of comparative effectiveness.
Rep. Nancy Pelosi (D-Calif.), Speaker of the House, will have to coordinate House efforts. She's been outspoken about her distrust of private health insurance companies.
Sen. Harry Reid (D-Nev.), Senate Majority Leader, is working with the White House and the committees on strategy and the possibility of budget reconciliation.
Kathleen Sebelius, Secretary, Department of Health and Human Services (HHS), will manage changes to Medicare and Medicaid and drive policy implementation.
With partisan politics squarely at the center of the debate, some question whether these players will achieve reform policy at all.
Vince Ventimiglia, senior vice president of B&D Consulting and former HHS assistant secretary, tells me some type of legislation will pass toward the end of the year.
"There remains the political imperative in avoiding the 21% doctor pay cuts under the [Medicare sustainable growth rate] and in providing mechanisms to provide insurance coverage for at least a portion of the enormous number of uninsured persons," he says. "The real question is what can be afforded in today's economic and political environment."
While Congress might be working hard to craft a bill, it will be industry's job to complete the far more difficult task of carrying out the new policies.
Julie Miller is editor-in-chief of MANAGED HEALTHCARE EXECUTIVE. She can be reached at julie.miller@advanstar.com
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More